(Reuters) -Only one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss were still taking the ...

Only one of four patients persisted with Novo Nordisk's (NVO) newer GLP-1 drugs, Wegovy or Ozempic, two years after taking the popular meds for weight loss, according to a Reuters' analysis of U.S ...

Who should receive Ozempic and GLP-1 drugs given their high demand and limited supply? Experts debate prioritizing those with ...

The next wave of obesity drugs could help people lose even more weight—and make some pharma companies a fortune.

Share on Pinterest GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound can affect people differently. BONNINSTUDIO/Stocksy United Misconceptions about the benefits and risks of GLP-1 drugs like ...

Pharmacist Mark Mikhael has lost 50 pounds over the past 12 months. He no longer has diabetes and finds himself "at my ideal body weight," with his cholesterol below 200 for the first time in 20 ...

The Dutch Healthcare Institute has advised against covering the popular weight loss medicine Wegovy in the basic health ...

Research shows the drug can cut the risk of serious cardiovascular issues like heart attack and stroke in certain patients.

Only one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss were still taking the popular ...

The analysis does not include details about why patients quit. But it does offer a longer view on the real-world experiences of patients taking the drugs than previous research that studied use ...

Most Patients Stop Using Wegovy, Ozempic for Weight Loss Within Two Years, Analysis Finds By Chad Terhune (Reuters) -Only one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic ...

July 10 (Reuters) - Only one in four U.S. patients prescribed Novo Nordisk’s (NOVOb.CO), opens new tab Wegovy or Ozempic for weight loss were still taking the popular medications two years later ...